Meeting the Demands of CAR-T Manufacturing.
CAR‑T therapies present unique manufacturing challenges, including patient‑specific workflows, complex genetic modification steps, strict chain‑of‑identity requirements, and the need for reproducible quality across batches. As a hyper-focused cell therapy CDMO, Cellipont is built to address these challenges with flexible, phase‑appropriate solutions that scale as your program advances.
Our teams work as an extension of your organization, aligning process design, analytics, manufacturing, and quality systems to ensure your CAR‑T therapy is produced reliably and compliantly at every stage of development.
End-to-End CAR-T CDMO Expertise
Cellipont’s CAR‑T services are led by multidisciplinary teams with deep experience across cell therapy development, analytical science, manufacturing sciences, and quality systems. We support both autologous and allogeneic CAR‑T workflows, enabling customized approaches tailored to your target indication, vector strategy, and clinical phase.
Our expertise spans:
- CAR‑T process development and optimization
- Transition from manual to automated workflows
- Genetic modification strategies
Scale‑up and scale‑out manufacturing - Process characterization and control strategy development
- CMC readiness and lifecycle planning
Robust CAR‑T manufacturing begins with well‑designed processes and analytics. Cellipont supports early‑stage and late‑stage programs with integrated development services, including:
- Cell isolation, activation, and expansion optimization
- Development and qualification of analytical methods for identity, purity, potency, safety, and strength
- In‑process controls and sampling strategies
- Analytical method transfer, qualification, and validation
- Stability and comparability planning
Our development approach ensures processes are designed with GMP translation in mind, reducing risk during tech transfer and scale‑up.
Cellipont’s manufacturing facility was designed specifically for advanced cell therapies, providing an optimal environment for CAR‑T development and production.
Facility highlights include:
- Modular GMP cleanrooms supporting multi‑product operations
- Redundant utilities, power, and environmental controls
- Unidirectional flow of personnel, materials, and waste
- On‑site QC laboratories with identical equipment to manufacturing suites
- Secure client access and program transparency
This infrastructure enables parallel program execution while maintaining strict segregation and compliance.
Cellipont offers access to a broad range of automated and analytical platforms that enhance consistency, scalability, and control across CAR‑T workflows. Our platform‑agnostic approach allows us to select the right tools based on your process requirements rather than forcing standardization.
Cellipont’s CAR‑T services are led by multidisciplinary teams with deep experience across cell therapy development, analytical science, manufacturing sciences, and quality systems. We support both autologous and allogeneic CAR‑T workflows, enabling customized approaches tailored to your target indication, vector strategy, and clinical phase.
Our expertise spans:
- CAR‑T process development and optimization
- Transition from manual to automated workflows
- Genetic modification strategies
Scale‑up and scale‑out manufacturing - Process characterization and control strategy development
- CMC readiness and lifecycle planning
Robust CAR‑T manufacturing begins with well‑designed processes and analytics. Cellipont supports early‑stage and late‑stage programs with integrated development services, including:
- Cell isolation, activation, and expansion optimization
- Development and qualification of analytical methods for identity, purity, potency, safety, and strength
- In‑process controls and sampling strategies
- Analytical method transfer, qualification, and validation
- Stability and comparability planning
Our development approach ensures processes are designed with GMP translation in mind, reducing risk during tech transfer and scale‑up.
Cellipont’s manufacturing facility was designed specifically for advanced cell therapies, providing an optimal environment for CAR‑T development and production.
Facility highlights include:
- Modular GMP cleanrooms supporting multi‑product operations
- Redundant utilities, power, and environmental controls
- Unidirectional flow of personnel, materials, and waste
- On‑site QC laboratories with identical equipment to manufacturing suites
- Secure client access and program transparency
This infrastructure enables parallel program execution while maintaining strict segregation and compliance.
Cellipont offers access to a broad range of automated and analytical platforms that enhance consistency, scalability, and control across CAR‑T workflows. Our platform‑agnostic approach allows us to select the right tools based on your process requirements rather than forcing standardization.
Key Capabilities
Our team's expertise in CAR-T CDMO manufacturing ensures your program benefits from best-in-class science, technology, and operational excellence.
GMP & Regulatory Compliance
Cellipont Bioservices is committed to the highest standards of quality and regulatory compliance:
- Adherence to FDA and EMA guidelines for cell and gene therapy CDMO services.
- Robust QA/QC systems, including electronic batch records, real-time monitoring, and comprehensive documentation.
Why Choose Cellipont Bioservice
Choosing the right manufacturing partner is critical for the success of your CAR-T cell therapy program. Here's why Cellipont stands out:
Purpose-Built Cell Therapy CDMO
Infrastructure and teams designed specifically for cell therapy manufacturing
Integrated Capabilities
Development, analytics, manufacturing, and QC under one roof
Flexible & Scalable Operations
Support for early‑stage through late‑stage clinical programs
Collaborative Partnership Model
Transparent communication and dedicated program management
Technology Agnostic Approach
Platforms selected to fit your process, not the other way around
What Our Clients Are Saying
"Partnering with Cellipont’s team of experts ensures that our groundbreaking therapies are manufactured to the highest standards, accelerating our progress toward delivering next-generation therapies for glioblastoma and other solid tumors."
"We are excited to collaborate with Cellipont Bioservices, leveraging their expertise in cell therapy manufacturing to carry out our mission of bringing innovative CAR-T cell therapies to patients in need."
Related Services
We support a wide range of therapeutic platforms:
FAQs
CAR‑T manufacturing typically includes cell collection, isolation and activation, genetic modification, expansion, harvest, formulation, fill/finish, cryopreservation, and release testing. Cellipont supports each step within an integrated GMP framework.
Yes. Our CAR-T CDMO services support both autologous and allogeneic workflows, with flexibility to accommodate different scale and automation requirements.
Our suites are designed to scale throughput while maintaining product consistency, enabling smooth transition from early‑phase to later‑phase clinical supply.
Cellipont follows a structured, phase‑appropriate analytical method transfer strategy. During early development and Phase I programs, methods are transferred from the client and assessed for robustness and suitability, with pre‑qualification performed where appropriate. As programs progress into Phase II/III and PPQ, methods are formally qualified or validated in alignment with ICH Q2(R2) expectations. This approach ensures analytical continuity while supporting regulatory readiness as CAR‑T programs advance.
Cellipont applies quality‑by‑design principles to CAR‑T process development and manufacturing. Critical process parameters and critical quality attributes are identified early through development and gap analysis activities, then monitored using defined in‑process controls. Process characterization, demonstration runs, and data‑driven optimization are used to establish control strategies that support reproducibility, scalability, and GMP compliance across patient‑specific and scale‑out manufacturing workflows.